RELENZA
These highlights do not include all the information needed to use RELENZA safely and effectively. See full prescribing information for RELENZA. RELENZA (zanamivir inhalation powder), for oral inhalation useInitial U.S. Approval: 1999
Approved
Approval ID
d7c3bcc3-0c0d-4068-fd80-88cf54a376ef
Product Type
HUMAN PRESCRIPTION DRUG LABEL
Effective Date
Oct 24, 2023
Manufacturers
FDA
GlaxoSmithKline LLC
DUNS: 167380711
Products 1
Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.
zanamivir
PRODUCT DETAILS
NDC Product Code0173-0681
Application NumberNDA021036
Marketing CategoryC73594
Route of AdministrationRESPIRATORY (INHALATION)
Effective DateOctober 19, 2021
Generic Namezanamivir
INGREDIENTS (2)
ZANAMIVIRActive
Quantity: 5 mg in 1 1
Code: L6O3XI777I
Classification: ACTIB
LACTOSE, UNSPECIFIED FORMInactive
Code: J2B2A4N98G
Classification: IACT